A Quality of Life Study in Patients With Migraines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

52 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare depressive characteristics in migraine patients to those observed in patients with epilepsy in a previous study, and determine whether those symptoms are unique to patients with epilepsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches

NCT00210912

Migraine

COMPLETED PHASE3

A Study of LY2951742 in Participants With Migraine

NCT01625988

Migraine Headache

COMPLETED PHASE2

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

NCT00109083

Migraine Headaches

COMPLETED PHASE2

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

NCT01513291

Migraine Headache

COMPLETED PHASE2

Abortive Treatment of Migraine With the Cefaly® Abortive Program Device

NCT03217968

Migraine

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A form of depression known as dysphoric-like disorder is common in people with epilepsy, which may significantly affect the quality of life in these people, as shown in a previous study. However, it is unclear if this depressive disorder is unique to patients with epilepsy. In order to assess whether these symptoms are unique and idiosyncratic to the epilepsy population, in this multi-center study, these dysphoric depressive features will be contrasted to those seen in patients with other neurologic or psychiatric conditions. Migraine is selected as one of the comparison disorders because it shares with epilepsy characteristics of being a recurrent episodic central nervous system disorder, and our site will only enroll patients with migraine headaches.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Headache Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years of age or older
* Have the diagnosis of migraine
* Have had no change in migraine medication(s) 30 days prior to study
* Achieve a satisfactory score on the Wide Range Achievement Test 3 (WRAT3) test at the screening visit
* Capable of completing self-reporting questionnaires
* Willing and able to provide written informed consent and comply with the study protocol

Exclusion Criteria

* Presence of a clinically significant comorbidity of an unstable or progressive nature
* Presence of major depression
* Participation in an investigational drug study within the past 30 days
* Inability to communicate well with site study personnel

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No